News | Defibrillator Monitors | July 28, 2023

GE HealthCare Recalls TruSignal SpO2 Sensors for Issues That May Reduce Defibrillation Energy, Expose Patients to Unintended Voltage, or Give Inaccurate Readings

GE HealthCare is recalling malfunctioning TruSignal sensors that may reduce the amount of energy sent to the heart during defibrillation without any notification to the care provider

GE HealthCare is recalling malfunctioning TruSignal sensors that may reduce the amount of energy sent to the heart during defibrillation without any notification to the care provider

July 28, 2023 — GE HealthCare is recalling malfunctioning TruSignal sensors that may reduce the amount of energy sent to the heart during defibrillation without any notification to the care provider, which could prevent delivery of lifesaving therapy in a critical situation. This issue is most hazardous to hospitalized patients who may need defibrillation for cardiac arrest. Affected sensors may also unintentionally expose patients to electrical currents from other sources or may provide inaccurate measurements of SpO2, which can impact treatment decisions.  

The U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries, serious health consequences, or death. 

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. 

Recalled Product  

Product Names:  

  • TruSignal Adult Pediatric Sensor  
  • TruSignal AllFit Sensor  
  • TruSignal Sensitive Skin Sensor  
  • TruSignal Wrap Sensor 
  • TruSignal Ear Sensor  
  • TruSignal Integrated Ear Sensor with GE Connector  
  • TruSignal Integrated Ear Sensor with Datex Connector  
  • TruSignal Integrated Ear Sensor with Datex Connector  
  • TruSignal Integrated Ear Sensor with Ohmeda Connector  

Distribution Dates: January 1, 2021 to March 4, 2023 

Devices Recalled in the U.S.: 7,559 

Date Initiated by Firm: May 19, 2023 

Device Use 

TruSignal sensors continuously monitor the amount of oxygen found in the blood flowing through the arteries (arterial oxygen saturation or SpO2) and pulse rate through a sensor placed on the skin. The sensors are designed and tested to help ensure patients have enough oxygen in their blood to keep their bodies functioning and to give care providers information to make treatment decisions.    

Reason for Recall  

GE HealthCare is recalling malfunctioning TruSignal sensors that may reduce the amount of energy sent to the heart during defibrillation without any notification to the care provider, which could prevent delivery of lifesaving therapy in a critical situation. This issue is most hazardous to hospitalized patients who may need defibrillation for cardiac arrest. Affected sensors may also unintentionally expose patients to electrical currents from other sources or may provide inaccurate measurements of SpO2, which can impact treatment decisions.  

Use of defective TruSignal SpO2 Sensors may cause serious injuries or death.  

GE HealthCare has received four reported injuries and no reported deaths for this issue.  

Who May be Affected  

  • Adults and children whose SpO2 and pulse rate are continuously monitored using TruSignal SpO2 sensors.  
  • Healthcare providers who use TruSignal SpO2 sensors to monitor adult and pediatric patients.  

What to Do  

On May 19, 2023 GE HealthCare sent affected customers an Urgent Medical Device Correction notice with the following recommended actions: 

  • Use an alternate method for SpO2 monitoring, including TruSignal Sensors not impacted or an alternate SpO2 device. 
  • If alternate methods are not available, use affected TruSignal SpO2 Sensors as long as they have not been saturated with fluids. 
  • Follow the below instructions if defibrillation is necessary when affected TruSignal SpO2 Sensors are being used:  
    • Remove the affected TruSignal SpO2 Sensor 
    • Defibrillate per hospital protocol  
    • Reattach the affected TruSignal SpO2 Sensor after defibrillation is no longer needed  
  • Confirm the Adult/Pediatric SpO2 sensors do not have material covering the emitter or detector before using.  
  • Discard the sensor and use another sensor if any additional material is found to be present. 
  • Make sure all potential users are made aware of this safety notification and the recommended actions, and retain this notice.  
  • Complete and return the acknowledgement form attached to the notice to [email protected].  

Contact Information  

Customers with questions or concerns should contact GE HealthCare Service at 1-800-437-1171 or their local service representative.  

Additional Resources:  

Medical Device Recall Database entry: TruSignal Adult Pediatric Sensor  

Medical Device Recall Database entry: TruSignal AllFit SensorExternal Link Disclaimer  

Medical Device Recall Database entry: TruSignal Sensitive Skin Sensor  

Medical Device Recall Database entry: TruSignal Wrap Sensor 

Medical Device Recall Database entry: TruSignal Ear Sensor  

Medical Device Recall Database entry: TruSignal Integrated Ear Sensor with GE Connector 

Medical Device Recall Database entry: TruSignal Integrated Ear Sensor with Datex Connector  

Medical Device Recall Database entry: TruSignal Integrated Ear Sensor with Datex Connector  

Medical Device Recall Database entry: TruSignal Integrated Ear Sensor with Ohmeda Connector  

How do I report a problem? 

Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program using the online form or call 1-800-332-1088 for more information on how to mail or fax the form.


Related Content

News | FDA

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | FDA

July 29, 2024 — CorVascular, a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) ...

Home July 29, 2024
Home
News | FDA

July 2, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott has issued a correction for its ...

Home July 02, 2024
Home
News | FDA

June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary ...

Home June 18, 2024
Home
News | FDA

June 17, 2024 — Elutia Inc., a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting ...

Home June 17, 2024
Home
News | FDA

June 13, 2024 — Xeltis, a leading developer of transformative implants that enable the natural creation of living and ...

Home June 13, 2024
Home
News | FDA

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea ...

Home June 03, 2024
Home
News | FDA

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

Home May 17, 2024
Home
News | FDA

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

Home May 15, 2024
Home
News | FDA

May 8, 2024 — The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our ...

Home May 08, 2024
Home
Subscribe Now